A 45-year-old male from rural India presents with a 3-month history of cough, fever, and night sweats. High-resolution CT chest shows the findings marked as **A** in the diagram: a thick-walled cavity (>1 cm) in the right upper lobe with surrounding tree-in-bud opacities and centrilobular nodules. Sputum CBNAAT is positive for *Mycobacterium tuberculosis* with no rifampin resistance. Which of the following is the most appropriate initial anti-TB regimen for this patient under India's NTEP?
A. 18 months HRZE daily without continuation phase
B. 2 months HRZE (isoniazid, rifampin, pyrazinamide, ethambutol) followed by 4 months HRE
C. 6 months BPaL (bedaquiline, pretomanid, linezolid) daily
D. 2 months HRE followed by 4 months HRZE
Explanation
Why option 1 is correct
The CT findings marked A — thick-walled cavity, tree-in-bud opacities, and centrilobular nodules — are pathognomonic for post-primary (reactivation) pulmonary tuberculosis caused by Mycobacterium tuberculosis. This patient has drug-sensitive TB (CBNAAT positive, no rifampin resistance). According to India's NTEP Technical Guidelines and WHO Consolidated TB Guidelines 2023, the standard regimen for drug-sensitive TB is a 6-month course: INTENSIVE PHASE of 2 months with HRZE (isoniazid, rifampin, pyrazinamide, ethambutol) followed by a CONTINUATION PHASE of 4 months with HRE (isoniazid, rifampin, ethambutol). This regimen achieves cure rates >95% in drug-sensitive TB.
Why each distractor is wrong
Option 2 (2 months HRE followed by 4 months HRZE): This reverses the correct sequence. Pyrazinamide is bactericidal and essential during the intensive phase to achieve rapid bacterial kill and prevent resistance. Removing it from the intensive phase compromises efficacy.
Option 3 (6 months BPaL): BPaL (bedaquiline, pretomanid, linezolid) is a newer all-oral regimen reserved for MDR-TB (resistance to isoniazid AND rifampin). This patient has drug-sensitive TB and does not require this more complex, expensive, and potentially more toxic regimen.
Option 4 (18 months HRZE without continuation phase): This is an outdated, prolonged regimen. Modern NTEP guidelines recommend 6 months total (2+4 months) for drug-sensitive TB. An 18-month course is unnecessarily long, reduces adherence, and increases adverse effects without additional benefit.
High-YieldNEET PG
Post-primary TB with cavitary disease and endobronchial spread (tree-in-bud + centrilobular nodules) = drug-sensitive TB → 2 months HRZE + 4 months HRE under NTEP.
WHO Consolidated TB Guidelines 2023; India NTEP Technical Guidelines
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
